Shared decision-making includes engaging patients, comparing treatments, and assessing patient values.
"[This drug] is so inexpensive that it can be prescribed immediately with no insurance issues and is affordable for many who have no insurance," Dr Metz said.
A variant in TNFSF13B, encoding the cytokine and drug target B-cell activating factor (BAFF), was associated with both multiple sclerosis and SLE.
Fifteen different classes of transcripts detected 4 circulating exosomal sequences within the miRNA category that were differentially expressed.
Over a 5-year follow-up, there was no correlation between 24-hour urine sodium levels and conversion to clinically definite MS.
The post-hoc analysis sought to identify factors predictive of relapse and disability progression in people with MS enrolled in the TRANSFORMS study.
Researchers sought to determine whether treatment with ocrelizumab improved measures of cognitive function better than interferon beta 1-a.
Initial trials of teriflunomide have demonstrated low lymphocyte counts in patients with relapsing forms of MS.
In patients with MS, hand function often correlates with measures of quality of life.
The prevalence of osteoporosis was greater in patients with MS than in matched controls.
Cognitive fatigue and anxiety are common symptoms reported by patients with multiple sclerosis.
Boys with onset of MS during puberty experienced an increased rate of relapse compared with boys with MS onset before or after puberty.
Radicava is the first approved treatment for ALS in over 20 years.
More accurate prediction of ALS prognosis can allow for better planned palliative care.
Longer studies are needed to further evaluate the effect of vitamin D supplementation on cognition in multiple sclerosis.
Increased risk of pediatric multiple sclerosis was observed in patients with prior exposure to EBV, HSV-1, and vitamin D deficiency.
In older patients with relapsing multiple sclerosis, patient-reported fatigue and problems with lower extremities may signal conversion to secondary progressive disease.
More participants achieved clinical NEDA with DMF than placebo over 2 years in the integrated analysis.
The biannual infusion is approved for the treatment of adults with relapsing and progressive forms of multiple sclerosis.
A study aimed to clarify the relationship between anxiety and depression in patients with multiple sclerosis.
Mindfulness meditation was associated with improvements in measures of anxiety, depression, and negative thoughts.
Opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.
Emflaza is approved for the treatment of Duchenne muscular dystrophy regardless of genetic etiology.
Several new multiple sclerosis drugs, including natalizumab, may be more effective at reducing relapses but still come with serious safety concerns.
Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.
Several microRNA were found to be associated with lesion volume and brain atrophy in multiple sclerosis.
Despite an elevated risk of PML, treatment with natalizumab results in slower disease progression than other treatments.
Patients with both MS and epileptic seizures had a younger age at onset of MS compared with those without seizures.
Researchers report 2 cases of a severe B-cell-mediated CNS disease after treatment with alemtuzumab in patients with multiple sclerosis.
Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Neurology Advisor Articles
- Growing Old Without Alzheimer's Pathology: What's the Secret?
- Minocycline May Slow Progression From Clinically Isolated Syndrome to Multiple Sclerosis
- Brain Inflammation Observed in Obsessive-Compulsive Disorder
- Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease
- Treating Post-Traumatic Headache After Concussion